Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read More
Tag: guselkumab
Janssen’s Tremfya wins psoriatic arthritis approval
The drug is the first IL-23 inhibitor approved for the condition
Read More
Tremfya tops Cosentyx in late-stage study
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
Read More
Tremfya gets FDA approval in moderate-to-severe plaque psoriasis
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
Read More
Janssen launches PhII/III programme testing Tremfya in Crohn’s
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Read More
Final NICE nod for Janssen’s Tremfya
The National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS.
Read More
SMC approves funding for six new therapies on the NHS
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
Janssen’s psoriasis biologic Tremfya shows long-term effect
Top-line trial data unveiled by Janssen at the 2018 American Academy of Dermatology (AAD) Annual Meeting over the weekend indicate that the benefit of Tremfya in patients with severe plaque psoriasis is maintained in the long-term.
Read More
UK launch for Janssen’s novel psoriasis biologic Tremfya
Janssen has announced the launch of Tremfya in the UK for adults with moderate to severe plaque psoriasis, following a green light from European regulators.
Read More
Janssen’s guselkumab shows long-term benefit in psoriasis
Janssen has unveiled new data showing consistent rates of skin clearance with guselkumab treatment among patients with moderate to severe plaque psoriasis.
Read More
Green light for Janssen Tremfya in the US
US regulators have issued a green light for Janssen Biotech’s new biologic Tremfya to treat moderate to severe plaque psoriasis.
Read More
Janssen brings psoriasis therapy guselkumab to the EMA
Janssen has filed its potential new psoriasis therapy guselkumab with the European Medicines Agency, hot on the heels of the drug’s submission in the US.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
